Skip to Main Content

Paper Details

MEK inhibition overcomes resistance to EphA2-targeted therapy in uterine cancer.
Gynecol Oncol
3
2021
-, BIM, BRAF, CRAF, EphA2, EphrinA1, HEC-1A, HEC-1A cells, HEC-1A model, HES1, Ishikawa, JAG1, Jagged 1, MAP3K15, MAPK, MEK, MYC, NOTCH family genes, NOTCH1, NOTCH3, c-MYC, cancer, cancer cells, carboplatin, dasatinib, dasatinib-resistant cells, dasatinib-resistant uterine cancer cells, endometrial cancer, pMAPK, paclitaxel, patients, resistant cells, trametinib, tumor, uterine cancer
Author NameAffiliation
Cristina IvanThe University of Texas MD Anderson Cancer Center, United States of America Center for RNA Interference and Non-Coding RNAs
Prahlad T RamThe University of Texas MD Anderson Cancer Center
Anil K SoodThe University of Texas MD Anderson Cancer Center, United States of America Center for RNA Interference and Non-Coding RNAs
  • 1 - 3

Datasets

Release 1.2